Introduction

The meniscus is a C-shaped piece of cartilage located in the knee joint, sandwiched between the femur (thigh bone) and tibia (shin bone). Each knee has two menisci—medial (inside) and lateral (outside)—which function as shock absorbers, stabilize the knee during movement, and help distribute weight evenly across the joint.

However, the meniscus has a significant anatomical limitation when it comes to healing: only the outer third, known as the "red zone," receives a rich blood supply. This vascularization is essential for healing because it delivers oxygen, nutrients, and healing cells. The inner two-thirds—the "white zone"—lack these critical resources, making natural healing of tears in this area difficult or, in many cases, impossible.

Traditional treatments include rest, physical therapy, or surgical options like partial meniscectomy (removal of the damaged part) or meniscal repair. While surgery can relieve symptoms in the short term, partial removal of the meniscus often compromises its function and accelerates cartilage wear, increasing the risk of osteoarthritis over time.

This is where regenerative medicine—and specifically, stem cell therapy—enters the picture.

Why Stem Cells Are Gaining Attention

Stem cell therapy is rooted in the body's innate ability to repair and regenerate damaged tissues. Mesenchymal stem cells (MSCs), in particular, are multipotent cells capable of differentiating into various types of connective tissue, including cartilage, bone, and fat. They also secrete bioactive molecules that promote healing in nearby tissues.

When introduced into the knee joint, MSCs can potentially:

• Stimulate repair of torn or degenerated meniscal tissue
• Reduce inflammation, offering symptomatic relief
• Modulate immune responses, preventing further joint degradation
• Promote angiogenesis, or the formation of new micro-blood vessels near tear sites
• Enhance extracellular matrix production, aiding structural restoration

In essence, stem cell therapy doesn’t merely mask symptoms—it seeks to address the root cause by encouraging actual tissue regeneration.

Types of Stem Cells Used

The source of stem cells can influence treatment outcomes. Most clinical applications and trials use mesenchymal stem cells derived from the following:

• Bone marrow: Often harvested from the iliac crest, bone marrow-derived MSCs are well-studied and known for their regenerative capabilities. However, the harvesting process is invasive and yields a lower cell count compared to other sources.
• Adipose (fat) tissue: Obtained through minimally invasive liposuction, adipose-derived stem cells are abundant and easier to harvest. They also exhibit strong anti-inflammatory effects.
• Synovial tissue: The lining of joints is another promising source of MSCs, particularly for intra-articular applications like meniscus repair. These cells show high proliferation rates and chondrogenic (cartilage-forming) potential.
• Umbilical cord or placental tissue: Used in research settings, these donor-derived allogeneic MSCs are collected post-birth and processed for therapeutic use. They offer off-the-shelf availability and avoid invasive harvesting.

The cells are typically isolated, purified, and injected directly into the knee joint under ultrasound or MRI guidance to ensure accurate delivery.

Clinical Evidence: What We Know So Far

Preclinical and Animal Studies

Animal models have provided strong foundational evidence for the use of stem cells in meniscal healing. Studies in rabbits, goats, and sheep have demonstrated:

• Enhanced meniscal regeneration

• Improved biomechanical integrity of the repaired tissue

• Reduced joint inflammation and cartilage degradation

One notable study found that MSCs delivered via scaffold into meniscal defects resulted in superior healing compared to scaffold-only controls, suggesting the cells play an active role in regeneration.

Early Human Trials and Observations

Although still limited in scale, early-phase clinical trials in humans show encouraging outcomes:

• Increased meniscal volume: MRI scans post-treatment often reveal a measurable increase in meniscus size, indicating tissue growth.
• Pain and function improvement: Patients frequently report reductions in pain, stiffness, and improved range of motion.
• Minimal side effects: Adverse events are rare and typically mild, such as temporary swelling or discomfort.

For instance, one study involving patients post-partial meniscectomy reported that intra-articular MSC injections led to approximately 24% increase in meniscus volume at one year compared to baseline. Another small case series demonstrated symptom relief and improved knee function in patients with meniscal tears who had failed conservative treatments.

Limitations and Unknowns

Despite the promise, stem cell therapy for meniscal tears is not yet a standard of care. Reasons include:

• Lack of large, randomized controlled trials (RCTs)

• Short follow-up durations in existing studies

• Heterogeneity in treatment protocols (cell source, dose, delivery method)

• Regulatory and ethical considerations around stem cell use

We are still learning whether the newly formed tissue offers the same durability and mechanical properties as native meniscus. Long-term outcomes, particularly beyond 5–10 years, remain largely undocumented.

Ideal Candidates for Stem Cell Therapy

At Seoul Yes Hospital, careful candidate selection is critical to maximizing the chances of success. Based on current evidence, the best candidates are:

• Younger to middle-aged adults with good general health and regenerative capacity
• Individuals with partial or moderate tears, especially in the red-white transition zone
• Patients with limited cartilage damage and minimal osteoarthritis

• Those who have failed conservative treatment but want to avoid surgery

• Active individuals—athletes or workers—looking to return to function without downtime from invasive procedures

Who May Not Be Suitable

• Patients with complete meniscal loss or severely degenerated tissue
• Individuals with advanced osteoarthritis, where the joint environment is hostile to regeneration
• Those with multiple previous surgeries and significant scar tissue

• Patients unwilling to adhere to a structured rehabilitation protocol post-injection

Realistic expectations are essential. Stem cell therapy enhances the body’s healing ability but does not “regrow” an entirely new meniscus in all cases.

Risks and Considerations

Although stem cell injections are generally safe, patients should be aware of the following:

• Cost: Procedures can be expensive and are not typically covered by insurance, especially in Korea or other regions where the therapy is classified as experimental.
• Variability: Differences in cell harvesting techniques, preparation, and practitioner experience can impact outcomes.
• Delayed response: Healing is gradual. Improvements may not be noticeable for several weeks or months.
• Repeat treatments: Some cases may require multiple injections for optimal results.
• Regulatory oversight: Ensure the clinic adheres to national and international safety and quality standards.

At reputable facilities like Seoul Yes Hospital, we use validated protocols, advanced imaging guidance, and sterile cell processing to reduce risks and improve consistency.

How Seoul Yes Hospital Approaches This Therapy

Our approach to regenerative care integrates science, safety, and personalization. Here’s what patients can expect:

1. Comprehensive Evaluation
   Each patient undergoes a detailed consultation, including:

   • Medical history and lifestyle assessment

   • Advanced imaging (MRI, ultrasound)

   • Tear characterization (location, size, chronicity)

2. Stepwise Care Approach
   We begin with conservative treatments—physical therapy, anti-inflammatory medications, joint offloading—before considering injections.
3. Custom Treatment Planning
   Based on diagnostic findings, we select the most appropriate:

   • Cell source (bone marrow, fat, synovial)

   • Delivery method (guided injection, surgical augmentation)

   • Adjuncts (e.g., PRP, growth factors, scaffolds)

4. Image-Guided Precision
   Injections are performed under ultrasound or fluoroscopic guidance to ensure accurate placement in the joint space or tear site.
5. Rehabilitation & Monitoring
   Recovery includes:

   • Initial bracing or offloading

   • Gradual physical therapy progression

   • Regular follow-ups and imaging to assess healing

6. Outcome Tracking
   We collect patient-reported outcomes, monitor joint health over time, and continuously refine protocols through research collaboration.

Final Thoughts

Stem cell therapy represents a frontier in non-surgical meniscus repair. For patients who are not ready—or not suitable—for invasive procedures, it offers a biologically intelligent alternative. While not yet a guaranteed fix, it holds significant promise for reducing pain, improving joint function, and potentially slowing the progression toward osteoarthritis.

At Seoul Yes Hospital, we combine medical innovation with compassionate, patient-first care. Our team of regenerative specialists works closely with each individual to find a treatment path that aligns with their goals, lifestyle, and long-term health.